Treatment with the investigational vaccine IFN-alpha Kinoid increased the number of systemic lupus erythematosus (SLE) patients achieving low disease activity, lessened their use of corticosteroids, and was well-tolerated, according to full results of a Phase 2b trial.

The findings, “IFN Kinoid in Systemic Lupus Erythematosus (SLE): Results from a Phase IIb, Randomized, Placebo-Controlled Study,” were presented at the 13th International Congress on Systemic Lupus Erythematosus (LUPUS 2019) by Frédéric Houssiau, MD, PhD, a professor at the Université Catholique de Louvain in Belgium, and the chairman of the trial.

The double-blind, placebo-controlled study (NCT02665364) assessed the effectiveness and safety of IFN-alpha Kinoid in patients with active SLE on standard-of-care therapy. A total of 185 adults with moderate-to-severe disease activity were enrolled in the study, conducted in Europe, Asia, U.S., North Africa, and Latin America.

For results of the study please click here.